AbCellera Biologics (Nasdaq: ABCL) said it will release top-line data from its Phase 2 trial of ABCL635, an antibody drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE